Ligand Pharmaceuticals Inc (LGND) is now in the Overvalued zone, suggesting that its current forward PS ratio of 14.95 is considered Overvalued compared with the five-year average of -11.25. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 157.57 to 201.13 according to relative valuation method. Compared to the current price of 202.55 USD , Ligand Pharmaceuticals Inc By Overvalued By 0.71%.

Relative Value

Fair Zone

157.57-201.13

Current Price：202.55

0.71%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Ligand Pharmaceuticals Inc (LGND) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Ligand Pharmaceuticals Inc (LGND) has a current Price-to-Book (P/B) ratio of 3.93. Compared to its 3-year average P/B ratio of 2.39, the current P/B ratio is approximately 64.67% higher. Relative to its 5-year average P/B ratio of 2.39, the current P/B ratio is about 64.81% higher. Ligand Pharmaceuticals Inc (LGND) has a Forward Free Cash Flow (FCF) yield of approximately 0.82%. Compared to its 3-year average FCF yield of 4.40%, the current FCF yield is approximately -81.31% lower. Relative to its 5-year average FCF yield of 4.49%, the current FCF yield is about -81.68% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LGND competitors is 19.60, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND.O) exhibits a P/S ratio of 14.95, which is -23.75% above the industry average. Given its robust revenue growth of 39.37%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LGND increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LGND in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LGND currently overvalued or undervalued?

Ligand Pharmaceuticals Inc (LGND) is now in the Overvalued zone, suggesting that its current forward PS ratio of 14.95 is considered Overvalued compared with the five-year average of -11.25. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 157.57 to 201.13 according to relative valuation method. Compared to the current price of 202.55 USD, Ligand Pharmaceuticals Inc is Overvalued By 0.71%.

What is Ligand Pharmaceuticals Inc (LGND) fair value?

LGND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 157.57 to 201.13 according to relative valuation method.

How does LGND's valuation metrics compare to the industry average?

The average P/S ratio for LGND's competitors is 19.60, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND) exhibits a P/S ratio of 14.95, which is -23.75% above the industry average. Given its robust revenue growth of 39.37%, this premium appears sustainable.

What is the current P/B ratio for Ligand Pharmaceuticals Inc (LGND) as of Mar 02 2026?

As of Mar 02 2026, Ligand Pharmaceuticals Inc (LGND) has a P/B ratio of 3.93. This indicates that the market values LGND at 3.93 times its book value.

What is the current FCF Yield for Ligand Pharmaceuticals Inc (LGND) as of Mar 02 2026?

As of Mar 02 2026, Ligand Pharmaceuticals Inc (LGND) has a FCF Yield of 0.82%. This means that for every dollar of Ligand Pharmaceuticals Inc's market capitalization, the company generates 0.82 cents in free cash flow.

What is the current Forward P/E ratio for Ligand Pharmaceuticals Inc (LGND) as of Mar 02 2026?

As of Mar 02 2026, Ligand Pharmaceuticals Inc (LGND) has a Forward P/E ratio of 35.39. This means the market is willing to pay $35.39 for every dollar of Ligand Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ligand Pharmaceuticals Inc (LGND) as of Mar 02 2026?

As of Mar 02 2026, Ligand Pharmaceuticals Inc (LGND) has a Forward P/S ratio of 14.95. This means the market is valuing LGND at $14.95 for every dollar of expected revenue over the next 12 months.

LGND Valuation